Phase I study of ARM 210 (S48168) for the treatment of Duchenne muscular dystrophy

Trial Profile

Phase I study of ARM 210 (S48168) for the treatment of Duchenne muscular dystrophy

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs ARM 210 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors ARMGO Pharma; Servier
  • Most Recent Events

    • 10 Dec 2014 New trial record
    • 04 Dec 2014 This trial is expected to begin in 2015 after receipt of input from regulatory agencies, according to a media release from ARMGO Pharma and Servier.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top